Antibodies to <i>Mycobacterium paratuberculosis</i>-specific protein antigens in Crohn's disease

Elsaghier, A.; Prantera, Cosimo; Moreno, Carlos; Iványi, J

doi:10.1111/j.1365-2249.1992.tb05874.x

Cited by 60 publications

(7 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PCR, in situ hybridization, and other molecular tools successfully detected MAP DNA in the tissues and blood samples of CD patients [5–7]. Immunological studies using specific, highly purified recombinant antigens also supported the association between MAP infection and cases of CD [8–10]. In the developed countries, “commercial ELISA kits” employed for the detection of MAP antibodies in animals have been successfully adopted for the screening of human serum samples [11, 12].…”

Section: Introductionmentioning

confidence: 99%

Evaluation of “Indigenous Absorbed ELISA Kit” for the Estimation of Seroprevalence ofMycobacterium aviumSubspeciesparatuberculosisAntibodies in Human Beings in North India

Singh

Verma

et al. 2011

ISRN Veterinary Science

View full text Add to dashboard Cite

In present pilot study aimed to estimate, presence of Mycobacterium avium subspecies paratuberculosis (MAP) antibodies in the human serum samples originating from North India using “Indigenous absorbed ELISA kit” (ELISA kit). The phase I, “ELISA kit” was optimized using protoplasmic antigen from native isolate of MAP “Indian Bison type” recovered from the biopsies of Crohn's disease patients. The phase II, sensitivity and specificity of the kit were estimated as 40.0 and 83.3%, respectively, when evaluated in 40 human serum samples (5 Crohn's disease and 22 ulcerative colitis patients and 13 healthy human subjects) with defined MAP status with respect to stool culture. Seroprevalence of MAP antibodies was higher in CD patients (80.0%) as compared to ulcerative colitis patients (4.5%) and normal human subjects (15.3%). The phase III, seroprevalence of MAP antibodies was estimated as 23.4%, on the basis of the screening of 452 human serum samples (without history) from different geographical regions of North India. Region-wise, 34.0, 33.3, 32.8, 25.0, 23.0, 17.7, and 12.5% samples were positive from the states of Punjab, Uttarakhand, New Delhi, Himachal Pradesh, Haryana, Uttar Pradesh and Jammu and Kashmir, respectively. Study reported moderately higher presence of MAP antibodies in human population, which necessitates programs to reduce the bioburden of MAP in the environment and in animal population.

show abstract

Section: Introductionmentioning

confidence: 99%

Evaluation of “Indigenous Absorbed ELISA Kit” for the Estimation of Seroprevalence ofMycobacterium aviumSubspeciesparatuberculosisAntibodies in Human Beings in North India

Singh

Verma

et al. 2011

ISRN Veterinary Science

View full text Add to dashboard Cite

show abstract

“…Among these organisms, high serum antibody titres for Caenorhabditis elegans [22,23] and Mycobacterium sp. [24] have been reported in inflammatory bowel disease. Interestingly, TCP‐353 might also represent the rice antigen O. sativa , considering the dietary habits of Japanese subjects.…”

Section: Discussionmentioning

confidence: 99%

Isolation and characterization of a novel short peptide associated with Crohn's disease

Mitsuyama

Niwa

Masuda

et al. 2011

Clinical and Experimental Immunology

View full text Add to dashboard Cite

SummaryPhage display technology has been utilized to select target molecules against circulating antibodies. The aims of this study were to isolate a peptide that binds with serum from Crohn's disease (CD) patients and to examine its diagnostic and pathogenic significance. A phage display library was constructed using cDNA from Caco-2 cells. Affinity selection using this cDNA library and serum samples from patients with CD was then performed. Phage clones that specifically reacted with the CD sera were then selected using a phage enzyme-linked immunosorbent assay (ELISA).After the DNA sequences of the selected phages were determined and converted to amino acid sequences, the synthesized peptides were examined using an ELISA. The effect of the synthesized peptides on cytokine release from cultured blood mononuclear cells was investigated. An ELISA analysis for TCP-353 demonstrated that while 61·7% of the samples from CD patients were seroreactive, seroreactivity was less common among patients with ulcerative colitis (7·3%), acute colitis (0%) or colon cancer (11·4%) and among normal subjects (2·8%). The induction of interleukin (IL)-1b, IL-6 and tumour necrosis factor (TNF)-a release, but not IL-10 release, in response to TCP-353 peptide was enhanced in CD mononuclear cells only. We isolated a novel peptide that specifically binds to CD sera and stimulates the proinflammatory responses of CD mononuclear cells. TCP-353 may have diagnostic, pathogenic and therapeutic significance with regard to the treatment of CD.

show abstract

“…Elevated serum antibodies to mycobacterial, but not to human hsp65 in Crohn’s disease, implied a pathogenic role of mycobacteria, whereas antibodies in ulcerative colitis bound to human hsp65 ( 53 ). Further support for the mycobacterial pathogenesis of Crohn’s disease came from the finding of elevated antibody levels against three different antigens derived from Mycobacterium paratuberculosis ( 54 ).…”

Section: Cross-reactivity Of Mycobacterial Epitopesmentioning

confidence: 99%

Function and Potentials of M. tuberculosis Epitopes

Iványi

2014

Front. Immunol.

View full text Add to dashboard Cite

Study of the function of epitopes of Mycobacterium tuberculosis antigens contributed significantly toward better understanding of the immunopathogenesis and to efforts for improving infection and disease control. Characterization of genetically permissively presented immunodominant epitopes has implications for the evolution of the host–parasite relationship, development of immunodiagnostic tests, and subunit prophylactic vaccines. Knowledge of the determinants of cross-sensitization, relevant to other pathogenic or environmental mycobacteria and to host constituents has advanced. Epitope-defined IFNγ assay kits became established for the specific detection of infection with tubercle bacilli both in humans and cattle. The CD4 T-cell epitope repertoire was found to be more narrow in patients with active disease than in latently infected subjects. However, differential diagnosis of active TB could not be made reliably merely on the basis of epitope recognition. The mechanisms by which HLA polymorphism can influence the development of multibacillary tuberculosis (TB) need further analysis of epitopes, recognized by Th2 helper cells for B-cell responses. Future vaccine development would benefit from better definition of protective epitopes and from improved construction and formulation of subunits with enhanced immunogenicity. Epitope-defined serology, due to its operational advantages is suitable for active case finding in selected high disease incidence populations, aiming for an early detection of infectious cases and hence for reducing the transmission of infection. The existing knowledge of HLA class I binding epitopes could be the basis for the construction of T-cell receptor-like ligands for immunotherapeutic application. Continued analysis of the functions of mycobacterial epitopes, recognized by T cells and antibodies, remains a fertile avenue in TB research.

show abstract

Antibodies to Mycobacterium paratuberculosis-specific protein antigens in Crohn's disease

Cited by 60 publications

References 22 publications

Evaluation of “Indigenous Absorbed ELISA Kit” for the Estimation of Seroprevalence ofMycobacterium aviumSubspeciesparatuberculosisAntibodies in Human Beings in North India

Evaluation of “Indigenous Absorbed ELISA Kit” for the Estimation of Seroprevalence ofMycobacterium aviumSubspeciesparatuberculosisAntibodies in Human Beings in North India

Isolation and characterization of a novel short peptide associated with Crohn's disease

Function and Potentials of M. tuberculosis Epitopes

Contact Info

Product

Resources

About